Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 56,196 shares, a growth of 76.8% from the September 30th total of 31,793 shares. Based on an average trading volume of 15,975 shares, the days-to-cover ratio is currently 3.5 days.
Medexus Pharmaceuticals Price Performance
Shares of OTCMKTS:MEDXF traded down $0.04 during midday trading on Friday, reaching $3.56. 1,030 shares of the company’s stock were exchanged, compared to its average volume of 13,084. Medexus Pharmaceuticals has a 12 month low of $1.80 and a 12 month high of $3.96. The company’s 50 day simple moving average is $3.56 and its two-hundred day simple moving average is $2.98.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company focused on acquiring, commercializing and supporting differentiated prescription products in North America. The company serves healthcare providers and patients primarily in the United States and Canada, with an emphasis on products addressing specialty and underserved therapeutic markets.
Medexus’ portfolio has included IXINITY, a recombinant factor IX replacement therapy used to prevent and control bleeding in people with hemophilia B; Rasuvo, a single-dose subcutaneous methotrexate injection used for certain rheumatoid arthritis and juvenile idiopathic arthritis patients; and Gleolan, an oral diagnostic imaging agent used during surgery to help visualize malignant glioma tissue.
The company’s business model is centered on licensing, acquiring and commercializing pharmaceutical products rather than conducting broad-based drug discovery.
Recommended Stories
- Five stocks we like better than Medexus Pharmaceuticals
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
